Eisai and Accenture Launch Clinical Data Management in India under Global Outsourcing Agreement
News Feb 14, 2008
Eisai Co., Ltd. and Accenture Japan., Ltd. announced that under the global outsourcing agreement signed between Eisai Medical Research Inc. and Accenture LLC, Accenture will provide Eisai with clinical data management services through its delivery center in Chennai, Tamil Nadu, India.
Starting full operation from February 13, 2008 after 3 weeks trial period, the service will cover Japan, the United States, and Europe. This is the first time a major Japanese pharmaceutical company has outsourced clinical data management services as a Business Process Outsourcing to India.
Clinical data management is a set of operational activities which includes data collection, processing, preparation for analysis, and archiving of clinical trial data. Eisai is working proactively to standardize its' clinical data management process to better deliver safe and effective pharmaceuticals to patients globally.
As part of this, the company is outsourcing data management operations to Accenture's Delivery Center in India where there is a concentration of the resources, expert expertise, and appropriate technology. Going forward, Eisai intends to expand its outsourcing to include electronic data capture (eDC) in order to improve the efficiency and timeliness of data collection and reporting. This provides additional flexibility in resourcing Eisai's activities.
Eisai intends to add value through the realization of its "transformation strategy". The transformation strategy is focused on the transfer of some of the company's primary operational functions to areas with quality technology and high cost effectiveness. As a part of this strategy, Eisai established a manufacturing and research subsidiary in India in December 2007.
Through this new strategic agreement, Eisai takes an additional step toward realization of its transformation. The agreement will enhance its capabilities in global clinical research and development, reduces operational costs, and shortens the development timelines.
Elpis BioMed Closes Funding Round to Commercialise Novel Technology Platform for Generating Human Cell TypesNews
New Cambridge spin-out company commercialises disruptive technology that enables rapid generation of pure and consistent batches of human cell types. Geographically diversified, top-tier investor team includes key industry leaders to support early company development.READ MORE
Quotient Sciences Acquires Pharmaterials, a UK-based Contract Development and Manufacturing OrganizationNews
Quotient Sciences, the drug development services organization, announces it has acquired Pharmaterials, a contract development and manufacturing organization (CDMO) based in Reading, U.K..READ MORE
BOC Sciences Continues to Enlarge Its Publication Collection Using BOC Sciences ProductsNews
BOC Sciences continues to add more publication items that used BOC Sciences products in their researches to its already existing collection.READ MORE